Genentech issues advisory on damaged Herceptin vials
There is a risk that damaged vials may lead to a loss in sterility.
Genentech has informed healthcare professionals that an increased number of complaints have been received regarding damaged and broken vials of Herceptin 440 mg and BWFI (bacteriostatic water for injection) diluent. The affected vials are NDC# 50242-0134-68, List # 15534.
There is a risk that damaged vials may lead to a loss in sterility, which can cause infections in patients, according to Genentech. The company, however, believes the risk to patients is negligible because of a low occurrence rate and the obviousness of the affected vials.
Healthcare professionals should inspect cartons of the product for signs of leakage, cracks, and other damage to the vials; observe the vials during reconstitution; and check for loss of vacuum in the containers.
The company said it has not identified any systemic error in the internal manufacturing process for Herceptin that would cause the damage.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
